Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Previous Hold Today AMRN ranks #2545 as HOLD CANDIDATE #2545 Next Hold

AMRN stock forecast Amarin Corporation PLC

AMRN stock forecast

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

Read more

The FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September.

Read more

Bulls shop at this discount retailer
04:40pm, Wednesday, 29'th May 2019
"Halftime Report" traders Jon and Pete Najarian spot unusual options activity in shares of TJX, Amarin, and Oil Services ETF (OIH).

Read more

Options traders say it's hip to be Square
04:04pm, Friday, 24'th May 2019
"Halftime Report" trader Jon Najarian spots unusual options activity in shares of Square and Amarin

Read more

Amarin's Q1 2019 report was basically as expected, although it didn't increase its revenue guidance for 2019. I believe that Amarin is still being fairly conser

Read more

The biotechnology space is an exciting one with incredible potential for investors. Moreover, due to the fact that several catalysts take place from the …

Read more

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank